What is Immunome's restricted cash?

Immunome (IMNM) reported restricted cash of $210K in Q1 2026.

How has Immunome's restricted cash changed year-over-year?

Immunome's restricted cash increased by 110.0% year-over-year, from $100K to $210K.

What is the long-term trend for Immunome's restricted cash?

Over 5 years (2020 to 2025), Immunome's restricted cash has grown at a 16.0% compound annual growth rate (CAGR), from $100K to $210K.

What does restricted cash mean?

Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

Immunome IMNM Restricted Cash

Restricted Cash at other companies

Arcus BiosciencesRCUS

$3M0.0%

SELLAS Life Sciences Group, Inc.SLS

$100K0.0%

IDEAYA Biosciences, Inc.IDYA

$1.28M+59.1%

Summit TherapeuticsSMMT

$316K-0.6%

Adaptive BiotechnologiesADPT

$2.71M-0.1%

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's restricted cash?: Immunome (IMNM) reported restricted cash of $210K in Q1 2026.
How has Immunome's restricted cash changed year-over-year?: Immunome's restricted cash increased by 110.0% year-over-year, from $100K to $210K.
What is the long-term trend for Immunome's restricted cash?: Over 5 years (2020 to 2025), Immunome's restricted cash has grown at a 16.0% compound annual growth rate (CAGR), from $100K to $210K.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.